

# 68 - References

## References

### Schizophrenia and related psychoses CHAPTER 1 References

1. Patel MX, et al. Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: de-escalation and rapid tranquillisation. *J Psychopharmacol* 2018; 32:601-640.
2. Bak M, et al. The pharmacological management of agitated and aggressive behaviour: a systematic review and meta-analysis. *Eur Psychiatry* 2019; 57:78-100.
3. deSouza IS, et al. Rapid tranquilization of the agitated patient in the emergency department: a systematic review and network meta-analysis. *Am J Emerg Med* 2022; 51:363-373.
4. Currier GW, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. *J Clin Psychiatry* 2004; 65:386-394.
5. Ganesan S, et al. Effectiveness of quetiapine for the management of aggressive psychosis in the emergency psychiatric setting: a naturalistic uncontrolled trial. *Int J Psychiatry Clin Pract* 2005; 9:199-203.
6. Simpson JR, Jr., et al. Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion, and restraint in an acute inpatient psychiatric setting. *J Clin Psychopharmacol* 2006; 26:333-335.
7. Hsu WY, et al. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. *J Clin Psychopharmacol* 2010; 30:230-234.
8. Pratts M, et al. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. *Acta Psychiatr Scand* 2014; 130:61-68.
9. Lesem MD, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. *Br J Psychiatry* 2011; 198:51-58.
10. Kwentus J, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. *Bipolar Disord* 2012; 14:31-40.
11. Allen MH, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* 2011; 72:1313-1321.

12. Karlin DM, et al. Dexmedetomidine sublingual film: a new treatment to reduce agitation in schizophrenia and bipolar disorders. *Ann Pharmacother* 2024; 58:54-64.
13. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. *J Clin Psychiatry* 2007; 68:1876-1885.
14. Paris G, et al. Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders: a systematic review and network meta-analysis. *Schizophr Res* 2021; 229:3-11.
15. Perrin E, et al. A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania. *Eur Psychiatry* 2012; 27:234-239.
16. Ferraz Goncalves JA, et al. Comparison of haloperidol alone and in combination with midazolam for the treatment of acute agitation in an inpatient palliative care service. *J Pain Palliat Care Pharmacother* 2016; 30:284-288.
17. Chan EW, et al. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. *Ann Emerg Med* 2013; 61:72-81.
18. TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. *BMJ* 2003; 327:708-713.
19. Raveendran NS, et al. Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. *BMJ* 2007; 335:865.
20. Huf G, et al. Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. *BMJ* 2007; 335:869.
21. Alexander J, et al. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. *Br J Psychiatry* 2004; 185:63-69.
22. Dib JE, et al. Rapid tranquillisation in a psychiatric emergency hospital in Lebanon: TREC--Lebanon: a pragmatic randomised controlled trial of intramuscular haloperidol and promethazine v. intramuscular haloperidol, promethazine and chlorpromazine. *Psychol Med* 2022; 52:2751-2759.
23. Taylor DM, et al. Midazolam-droperidol, droperidol, or olanzapine for acute agitation: a randomized clinical trial. *Ann Emerg Med* 2017; 69:318-326.e1.
24. Kittipeerachon M, et al. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: a pragmatic double-blind randomized trial. *Schizophr Res* 2016; 176:231-238.
25. Klein LR, et al. Intramuscular midazolam, olanzapine, ziprasidone, or haloperidol for treating acute agitation in the emergency department. *Ann Emerg Med* 2018; 72:374-385.
26. Huang CL, et al. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: an open-label, randomized controlled trial. *J Formos Med Assoc* 2015; 114:438-445.
27. Calver L, et al. The safety and effectiveness of droperidol for sedation of acute behavioral disturbance in the emergency department. *Ann Emerg Med* 2015; 66:230-238.e1.

28. Thiemann P, et al. Prospective study of haloperidol plus lorazepam versus droperidol plus midazolam for the treatment of acute agitation in the emergency department. *Am J Emerg Med* 2022; 55:76-81.
29. Powney MJ, et al. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). *Cochrane Database Syst Rev* 2012; 11:CD009377.
30. Ostinelli EG, et al. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). *Cochrane Database Syst Rev* 2017; 7:CD009377.

72 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 31. National Institute for Health and Care Excellence. Violence and aggression: short-term management in mental health, health and community settings. NICE guideline [NG10]. 2015 (reviewed May 2023, last checked December 2024); <https://www.nice.org.uk/guidance/NG10>. 32. Huf G, et al. Haloperidol plus promethazine for psychosis-induced aggression. *Cochrane Database Syst Rev* 2016; 11:CD005146. 33. Kishi T, et al. Intramuscular olanzapine for agitated patients: a systematic review and meta-analysis of randomized controlled trials. *J Psychiatr Res* 2015; 68:198-209. 34. Khokhar MA, et al. Droperidol for psychosis-induced aggression or agitation. *Cochrane Database Syst Rev* 2016; 12:CD002830. 35. Satterthwaite TD, et al. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. *J Clin Psychiatry* 2008; 69:1869-1879. 36. van Harten PN, et al. Acute dystonia induced by drug treatment. *BMJ* 1999; 319:623-626. 37. Pharmacovigilance Working Party. Public Assessment Report on Neuroleptics and Cardiac safety, in particular QT prolongation, cardiac arrhythmias, ventricular tachycardia and torsades de pointes. 2006. 38. Essential Pharma Ltd (Malta). Summary of Product Characteristics. HALDOL Decanoate (haloperidol decanoate) 100 mg/ml solution for injection. 2023 (last checked December 2024); <https://www.medicines.org.uk/emc/product/15246/smpc>. 39. Miceli JJ, et al. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. *Clin Ther* 2010; 32:472-491. 40. Suzuki A, et al. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. *Ther Drug Monit* 2003; 25:192-196. 41. Lerner Y, et al. Acute high-dose parenteral haloperidol treatment of psychosis. *Am J Psychiatry* 1979; 136:1061-1064. 42. Martel ML, et al. A large retrospective cohort of patients receiving intravenous olanzapine in the emergency department. *Acad Emerg Med* 2016; 23:29-35. 43. Cole JB, et al. A prospective observational study of patients receiving intravenous and intramuscular olanzapine in the emergency department. *Ann Emerg Med* 2017; 69:327-336.e2. 44. Calver L, et al. A prospective study of high dose sedation for rapid tranquillisation of acute behavioural disturbance in an acute mental health unit. *BMC Psychiatry* 2013; 13:225. 45. Mantovani C, et al. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions. *J Clin Psychopharmacol* 2013; 33:306-312. 46. Taylor D, et al. Buccal midazolam for rapid tranquillisation. *Int J Psychiatry Clin Pract* 2008; 12:309-311. 47. Spain D, et al. Safety and effectiveness of high-dose midazolam for severe behavioural disturbance in an emergency department with suspected psychostimulant-affected patients. *Emerg Med Australas* 2008; 20:112-120. 48. Chan EW, et al. Intramuscular midazolam, olanzapine, or haloperidol for the management of acute agitation: a multi-centre, double-blind, randomised clinical trial. *EClinicalMedicine* 2021; 32:100751. 49. Zaman H, et al. Benzodiazepines for psychosis-induced aggression or agitation. *Cochrane Database Syst Rev* 2017; 12:CD003079. 50. Li SF, et al. Safety and efficacy of intravenous combination sedatives in the ED. *Am J Emerg Med* 2013; 31:1402-1404.

51. MacNeal JJ, et al. Use of haloperidol in PCP-intoxicated individuals. *Clin Toxicol (Phila)* 2012; 50:851-853. 52. Mankowitz SL, et al. Ketamine for rapid sedation of agitated patients in the prehospital and emergency department settings: a systematic review and proportional meta-analysis. *J Emerg Med* 2018; 55:670-681. 53. Kim HK, et al. Safety and efficacy of pharmacologic agents used for rapid tranquilization of emergency department patients with acute agitation or excited delirium. *Expert Opin Drug Saf* 2021; 20:123-138. 54. Pierre JM. Time to retire haloperidol? For emergency agitation, evidence suggests newer alternatives may be a better choice. *Current Psychiatry* 2020; 19:18-28. 55. Huf G, et al. Physical restraints versus seclusion room for management of people with acute aggression or agitation due to psychotic illness (TREC-SAVE): a randomized trial. *Psychol Med* 2012; 42:2265-2273. 56. Amdisen A, et al. Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in Viscoleo. *Psychopharmacology (Berl)* 1986; 90:412-416. 57. Amdisen A, et al. Zuclopenthixol acetate in viscoleo: a new drug formulation. An open Nordic multicentre study of zuclopenthixol acetate in Viscoleo in patients with acute psychoses including mania and exacerbation of chronic psychoses. *Acta Psychiatr Scand* 1987; 75:99-107. 58. Lowert AC, et al. Acute psychotic disorders treated with 5% zuclopenthixol acetate in 'Viscoleo' ('Cisordinol--Acutard'), a global assessment of the clinical effect: an open multi-centre study. *Pharmatherapeutica* 1989; 5:380-386. 59. Balant LP, et al. Clinical and pharmacokinetic evaluation of zuclopenthixol acetate in Viscoleo. *Pharmacopsychiatry* 1989; 22:250-254. 60. Chakravarti SK, et al. Zuclopenthixol acetate (5% in 'Viscoleo'): single-dose treatment for acutely disturbed psychotic patients. *Curr Med Res Opin* 1990; 12:58-65. 61. Baastrup PC, et al. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. *Acta Psychiatr Scand* 1993; 87:48-58. 62. Chin CN, et al. A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics. *Med J Malaysia* 1998; 53:365-371. 63. Taymeeyapradit U, et al. Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients. *J Med Assoc Thai* 2002; 85:1301-1308. 64. Brook S, et al. A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. *Hum Psychopharmacol* 1998; 13:17-20. 65. Chouinard G, et al. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. *J Clin Psychopharmacol* 1994; 14:377-384.

Schizophrenia and related psychoses CHAPTER 1 66. Al-Haddad MK, et al. Zuclopenthixol versus haloperidol in the initial treatment of schizophrenic psychoses, affective psychoses and paranoid states: a controlled clinical trial. *Arab J Psychiatry* 1996; 7:44-54. 67. Garriga M, et al. Assessment and management of agitation in psychiatry: expert consensus. *World J Biol Psychiatry* 2016; 17:86-128. 68. Wilson MP, et al. Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients. *J Emerg Med* 2012; 43:889-896. 69. Villari V, et al. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. *Prog Neuropsychopharmacol Biol Psychiatry* 2008; 32:405-413. 70. Paton C. Benzodiazepines and disinhibition: a review. *Psychiatr Bull* 2002; 26:460-462. 71. Chan-Tack KM. Neuroleptic malignant syndrome due to promethazine. *South Med J* 1999; 92:1017-1018. 72. Appleby L, et al. Sudden unexplained death in psychiatric in-patients. *Br J Psychiatry* 2000; 176:405-406. 73. Yap YG, et al. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. *BMJ* 2000; 320:1158-1159. 74. Taylor DM. Antipsychotics and QT prolongation. *Acta Psychiatr Scand* 2003; 107:85-95. 75. Penninga EI, et al. Adverse events

associated with flumazenil treatment for the management of suspected benzodiazepine intoxication: a systematic review with meta-analyses of randomised trials. *Basic Clin Pharmacol Toxicol* 2016; 118:37-44.

---

Revision #1

Created 2026-01-04 20:13:53 UTC by Omar Ayman

Updated 2026-01-04 20:13:53 UTC by Omar Ayman